Eli Lilly Announces $3 Billion Wisconsin Manufacturing Expansion

The investment will create 750 jobs and boost production of diabetes and obesity drugs to meet rising demand.

Eli Lilly plans to expand its recently acquired manufacturing facility in Pleasant Prairie, Wisconsin, with a $3 billion investment.
The project will add 750 jobs, with roles ranging from operators to engineers, and is set to begin construction in 2025.
The expansion aims to increase production of Lilly’s blockbuster diabetes and obesity drugs, Mounjaro and Zepbound, as well as future medicines.
This marks Lilly's largest U.S. manufacturing investment outside of Indiana, contributing to its $23 billion global manufacturing expansion since 2020.
The company is collaborating with Wisconsin officials on tax incentives and workforce training programs to support the development.